AR040960A1 - Derivados de tiazol - Google Patents
Derivados de tiazolInfo
- Publication number
- AR040960A1 AR040960A1 ARP030102807A ARP030102807A AR040960A1 AR 040960 A1 AR040960 A1 AR 040960A1 AR P030102807 A ARP030102807 A AR P030102807A AR P030102807 A ARP030102807 A AR P030102807A AR 040960 A1 AR040960 A1 AR 040960A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- cycloalkyl
- aryl
- alkyl
- heteroaryl
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Compuestos de la fórmula (1) en donde: R1 es arilo o heteroarilo, en donde al menos una de las dos posiciones meta de cada grupo arilo y heteroarilo está sustituido con R5; R2 es hidrógeno, alquilo o cicloalquilo; R3 es cicloalquilo, arilo o heteroarilo, en donde al menos una de las dos posiciones orto de cada grupo cicloalquilo, arilo y heteroarilo está sustituido con R6; R4 es hidrógeno, alquilo o cicloalquilo; R5 es hidrógeno, ciano, trifluorometilo, alquil-SO2-, amino-SO2-, halógeno, alcoxilo, alquilcarbonilo o aminocarbonilo; R6 es hidrógeno, halógeno, ciano, nitro, trifluorometilo, alquilo, alcoxilo, hidroxilo o alcoxicarbonilo; y sales y ésteres farmacéuticamente aceptables de los mismos; con la condición que uno de R5 y R6 no sea hidrógeno. Reivindicación 16: Compuestos de acuerdo con cualquiera de las reivindicaciones de 1 a 13 para la preparación de medicamentos para la prevención y terapia de enfermedades que están causadas por trastornos asociadas con el receptor NPY. Reivindicación 18: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones de 1 a 13 para la preparación de medicamentos para el tratamiento y prevención de artritis, diabetes, trastornos alimenticios y obesidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02017677 | 2002-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040960A1 true AR040960A1 (es) | 2005-04-27 |
Family
ID=31502696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102807A AR040960A1 (es) | 2002-08-07 | 2003-08-05 | Derivados de tiazol |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7253197B2 (es) |
| EP (1) | EP1539722A1 (es) |
| JP (1) | JP2006502131A (es) |
| CN (1) | CN100381429C (es) |
| AR (1) | AR040960A1 (es) |
| AU (1) | AU2003253364B2 (es) |
| BR (1) | BR0313278A (es) |
| CA (1) | CA2493712A1 (es) |
| GT (1) | GT200300167A (es) |
| MX (1) | MXPA05001328A (es) |
| PA (1) | PA8579301A1 (es) |
| PL (1) | PL375416A1 (es) |
| RU (1) | RU2324685C2 (es) |
| TW (1) | TW200412947A (es) |
| UY (1) | UY27930A1 (es) |
| WO (1) | WO2004014884A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2297437T3 (es) | 2003-08-12 | 2008-05-01 | F. Hoffmann-La Roche Ag | Npy-antagonistas de 2-amino-5-benzoiltiazol. |
| ATE384058T1 (de) * | 2003-12-08 | 2008-02-15 | Hoffmann La Roche | Thiazolderivate |
| HUE025659T2 (en) * | 2003-12-26 | 2016-04-28 | Kyowa Hakko Kirin Co Ltd | Thiazole derivatives |
| US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| CA2562075C (en) * | 2004-04-20 | 2012-08-14 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| SG159561A1 (en) * | 2005-05-09 | 2010-03-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
| CA2634442A1 (en) * | 2005-12-22 | 2007-07-05 | Icagen, Inc. | Calcium channel antagonists |
| EP2320738A4 (en) * | 2008-08-29 | 2011-08-24 | Transtech Pharma Inc | SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF |
| WO2010098298A1 (ja) * | 2009-02-27 | 2010-09-02 | 塩野義製薬株式会社 | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 |
| US8871944B2 (en) | 2009-03-10 | 2014-10-28 | Gifu University | Thiazole derivative and process for producing same |
| JP7193071B2 (ja) * | 2017-02-08 | 2022-12-20 | 国立大学法人東海国立大学機構 | 蛍光発光材料および紫外線吸収剤 |
| CN113164419A (zh) | 2018-09-07 | 2021-07-23 | 皮克医疗公司 | Eif4e抑制剂和其用途 |
| BR112022017727A2 (pt) | 2020-03-03 | 2022-11-16 | Pic Therapeutics Inc | Inibidores de eif4e e usos dos mesmos |
| US20230167078A1 (en) | 2020-04-24 | 2023-06-01 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| EP4392422A1 (en) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US39275A (en) * | 1863-07-21 | Machine for compressing carriage-wheels | ||
| US4035367A (en) | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| US4649146A (en) * | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6569878B1 (en) * | 1997-10-27 | 2003-05-27 | Agouron Pharmaceuticals Inc. | Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| BR9912979B1 (pt) | 1998-08-14 | 2010-09-21 | composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan. | |
| JP3774118B2 (ja) | 1998-08-14 | 2006-05-10 | エフ．ホフマン−ラ ロシュ アーゲー | リパーゼ阻害剤を含む製薬学的組成物 |
| CZ20021086A3 (cs) | 1999-09-30 | 2002-10-16 | Neurogen Corporation | Alkylendiaminem substituované heterocykly |
| US20010039275A1 (en) | 2000-02-04 | 2001-11-08 | Bowler Andrew Neil | Use of 2,4-diaminothiazole derivatives |
| AU2001246494A1 (en) * | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| EP1395564B1 (en) | 2001-05-21 | 2008-02-27 | F. Hoffmann-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide y receptor |
| CA2455753A1 (en) | 2001-08-03 | 2003-02-13 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
-
2003
- 2003-07-31 PL PL03375416A patent/PL375416A1/xx not_active Application Discontinuation
- 2003-07-31 RU RU2005106201/04A patent/RU2324685C2/ru not_active IP Right Cessation
- 2003-07-31 WO PCT/EP2003/008473 patent/WO2004014884A1/en active IP Right Grant
- 2003-07-31 CA CA002493712A patent/CA2493712A1/en not_active Abandoned
- 2003-07-31 BR BR0313278-1A patent/BR0313278A/pt not_active IP Right Cessation
- 2003-07-31 CN CNB038186861A patent/CN100381429C/zh not_active Expired - Fee Related
- 2003-07-31 MX MXPA05001328A patent/MXPA05001328A/es unknown
- 2003-07-31 AU AU2003253364A patent/AU2003253364B2/en not_active Ceased
- 2003-07-31 EP EP03784122A patent/EP1539722A1/en not_active Withdrawn
- 2003-07-31 JP JP2004526832A patent/JP2006502131A/ja active Pending
- 2003-08-04 TW TW092121281A patent/TW200412947A/zh unknown
- 2003-08-04 PA PA20038579301A patent/PA8579301A1/es unknown
- 2003-08-05 GT GT200300167A patent/GT200300167A/es unknown
- 2003-08-05 UY UY27930A patent/UY27930A1/es not_active Application Discontinuation
- 2003-08-05 AR ARP030102807A patent/AR040960A1/es not_active Application Discontinuation
- 2003-08-05 US US10/634,431 patent/US7253197B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR0313278A (pt) | 2005-07-05 |
| PL375416A1 (en) | 2005-11-28 |
| RU2005106201A (ru) | 2006-11-20 |
| JP2006502131A (ja) | 2006-01-19 |
| AU2003253364A1 (en) | 2004-02-25 |
| CN1675188A (zh) | 2005-09-28 |
| CN100381429C (zh) | 2008-04-16 |
| UY27930A1 (es) | 2003-12-31 |
| RU2324685C2 (ru) | 2008-05-20 |
| US7253197B2 (en) | 2007-08-07 |
| AU2003253364B2 (en) | 2007-06-07 |
| WO2004014884A1 (en) | 2004-02-19 |
| GT200300167A (es) | 2004-03-16 |
| US20040038990A1 (en) | 2004-02-26 |
| EP1539722A1 (en) | 2005-06-15 |
| MXPA05001328A (es) | 2005-04-28 |
| TW200412947A (en) | 2004-08-01 |
| CA2493712A1 (en) | 2004-02-19 |
| PA8579301A1 (es) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040960A1 (es) | Derivados de tiazol | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| AR037682A1 (es) | Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas | |
| AR029815A1 (es) | Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| BRPI0718714B8 (pt) | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende | |
| AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
| AR057023A1 (es) | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
| PA8545301A1 (es) | Nuevos derivados de quinolina | |
| BRPI0407810A (pt) | composto, composição farmacêutica, ativador da glicocinase, e, medicamento | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| BRPI0512916A (pt) | derivado de tienopirazol tendo atividade inibidora de pde 7 | |
| CR7643A (es) | Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR069524A1 (es) | Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento | |
| AR044856A1 (es) | Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. | |
| AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
| AR058389A1 (es) | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad | |
| AR058800A1 (es) | Heterociclos condensados con anillos bencenicos como inhibidores de comt, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento del mal de parkinson | |
| BR112014004235A2 (pt) | derivados de isoxazolina como compostos inseticidas | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |